Section Arrow
GRFS.NASDAQ
- Grifols SA
Quotes are at least 15-min delayed:2024/10/31 21:11 EDT
Last
 8.71
-0.06 (-0.68%)
Day High 
8.755 
Prev. Close
8.77 
1-M High
9.09 
Volume 
1.37M 
Bid
8.6
Ask
9.03
Day Low
8.51 
Open
8.62 
1-M Low
8.11 
Market Cap 
5.96B 
Currency USD 
P/E 33.65 
%Yield 5.25 
10-SMA 8.64 
20-SMA 8.67 
50-SMA 8.78 
52-W High 12.1499 
52-W Low 5.3001 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
0.24/0.65
Enterprise Value
15.18B
Balance Sheet
Book Value Per Share
9.16
Cash Flow
Cash Flow Yield
0.07
Income Statement
Total Revenue
4.05B
Operating Revenue Per Share
9.66
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
PFEPfizer28.3-0.22-0.77%76.86PE
BMYBristol-Myers Squibb Co55.77+3.11+5.91%11.67PE
MRKMerck & Co102.32-2.51-2.39%19.39PE
GSKGSK plc36.76-0.25-0.68%12.75PE
ABBVABBVIE203.87+2.37+1.18%67.54PE
Quotes are at least 15-min delayed:2024/10/31 21:11 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and following the firm's Biotest acquisition in April 2022, the biopharma business contributed 84% of sales in 2023. Grifols also has smaller segments including diagnostics (10% of sales) and biosupplies.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.